Axon Enterprise delivered its first guidance step-down of the year, and the quarter fell short on both lines. Non-GAAP earnings of $1.72 per share missed the $1.90 consensus by 7.0% and came in below the $1.85 Earnings Whisper number. Revenue of $908.55 million missed by 2.4%. Earnings still grew 41.0% year over year and revenue rose 27.8%, but top-line growth has now decelerated for three straight quarters, from 39% in the fourth quarter of 2025 to 34%, 35% and now 28%. That is the central tension. Axon's highest-quality business is accelerating, while the hardware-heavy growth engines layered on top of it are producing lumpier revenue, thinner margins and weaker cash flow.

The quality of the quarter deserves scrutiny beneath the year-over-year gains. GAAP net income of $57 million, or $0.68 per share, swung from a $0.03 loss a year ago. However, $59.5 million of other income, primarily gains on strategic investments, did much of the lifting below the operating line. GAAP operating income was $42 million, down from $47 million in the second quarter. On a sequential basis, non-GAAP EPS fell from $1.88. Adjusted gross margin dropped to 59.2% from 62.9% in the second quarter and 62.7% a year ago. Connected Devices was the clear weak spot, where adjusted gross margin collapsed to 44.6% from 53.4%. Management attributed that decline to counter-drone equipment mix, higher memory costs and the absence of prior-quarter tariff refunds. Free cash flow was an outflow of $19 million after roughly $100 million went into a strategic inventory build.

The software story, by contrast, strengthened. Software & Services revenue grew 43% to $437 million, up from 36% growth in the second quarter. ARR reached $1.75 billion, up 40%, and net revenue retention held at 126%. Newer offerings, including real-time operations, Records, AI, 911 and Dedrone software, now run at nearly $500 million annualized, more than double last year's level. AI ARR passed $100 million. Future contracted bookings rose to $15.8 billion from $15.1 billion. Software-only gross margin remains above 80%, although segment margins slipped on professional services mix and new-product scaling. The call preserved a credible recurring-revenue growth story. It simply sits inside a consolidated model that is now harder to forecast.

The guidance cut is the development investors will focus on. Management removed about $130 million of federal Dedrone revenue from 2026, including a $30 million third-quarter deployment and $100 million expected in the fourth quarter. That reduces full-year growth to roughly 30% from the prior 32% to 34% range. Management argues growth would otherwise have exceeded prior guidance, but that is a counterfactual, not a result. Free cash flow guidance fell to $350 million to $400 million from about $450 million, and the return to 60% conversion was pushed to 2028. Bears have legitimate ammunition in several other areas:

• Memory cost pressure is expected to more than quadruple in 2027 from roughly 50 basis points this year.
• Year-to-date bookings growth is tracking above 20%, short of the roughly 30% normalized pace management discussed last quarter.
• TASER revenue declined year over year.
• The Apollo dart has slipped.
• Management flagged a possible body-camera refresh pause in the first quarter of 2027 ahead of Axon Body 5 shipments.

The call's tone turned noticeably more defensive, including talk of resetting how the company guides.

The offsets are real but longer-dated. The $1.2 billion Skydio investment, funded roughly 60/40 cash and stock, raises Axon's stake to 37% and secures exclusive public-safety distribution in the U.S. and Canada. That revenue will be recognized on a net basis within Software & Services. Axon Body 5 should start a new upgrade cycle in spring 2027. Federal bookings are up more than fivefold year to date, and two nine-figure state corrections deals underscore deal size. However, the $1.15 billion convertible raise pushed net debt to $1.2 billion.

The stock entered the report already badly bruised. Shares stood at $424.18, down 28.0% from the open after the August report and 34.9% below the inter-earnings high of $651.61 set on August 19. The stock was 10.7% under its 200-day moving average, though still 12.5% above the October 19 low of $377. Investor sentiment remained negative but improved, moving from -0.19 to -0.11, which suggests expectations were already subdued. The Earnings Whispers trend readings are mixed: sequential growth and momentum are positive, while price and AVWAP remain negative.

The bottom line is that Axon's software franchise is getting better, but this quarter broke the pattern of beat-and-raise execution. The miss, the lower revenue and cash-flow targets, and rising cost pressures shift the burden of proof to 2027 hardware deployments and the Skydio bet.